PRNewsWire
27 Sept 2026, 03:03 UTC · 9h ago
Verdict
Headline takes no side. Three claims average +0.67 — strongly bullish.
+0.67strongly bullish
More positive than 98% of claims this week
Scored by the NIS engine · methodology.
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
IASO206 demonstrated a 90% objective response rate and a 90% MRD negativity rate in patients with relapsed/refractory multiple myeloma.
Newannounced today, Sep 26, 2026
So whatThe 100% success rate in the high-dose cohort suggests potential for superior efficacy over existing BCMA therapies in high-risk populations.
More positive than 99% of claims this week
Continue reading
5 related stories
Top 1 mover · tap to explore
The therapy generates functional CAR-T cells in vivo via a single intravenous infusion, eliminating the need for lymphodepleting chemotherapy and ex vivo manufacturing.
Newannounced today, Sep 26, 2026
More positive than 98% of claims this week
No dose-limiting toxicities, ICANS, or treatment-related deaths were reported across the 10 evaluable patients.
Newannounced today, Sep 26, 2026
More positive than 87% of claims this week
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
